BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 16173788)

  • 1. Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti-CEA antibodies with taxol.
    Crow DM; Williams L; Colcher D; Wong JY; Raubitschek A; Shively JE
    Bioconjug Chem; 2005; 16(5):1117-25. PubMed ID: 16173788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic therapy of breast cancer with Y-90-chimeric L6 and paclitaxel in the xenografted mouse model: development of a clinical protocol.
    Denardo SJ; Richman CM; Kukis DL; Shen S; Lamborn KR; Miers LA; Kroger LA; Perez EA; Denardo GL
    Anticancer Res; 1998; 18(6A):4011-8. PubMed ID: 9891439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy.
    Clarke K; Lee FT; Brechbiel MW; Smyth FE; Old LJ; Scott AM
    Clin Cancer Res; 2000 Sep; 6(9):3621-8. PubMed ID: 10999754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biodistribution and radioimmunotherapy of human breast cancer xenografts with radiometal-labeled DOTA conjugated anti-HER2/neu antibody 4D5.
    Tsai SW; Sun Y; Williams LE; Raubitschek AA; Wu AM; Shively JE
    Bioconjug Chem; 2000; 11(3):327-34. PubMed ID: 10821648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.
    Behr TM; Wulst E; Radetzky S; Blumenthal RD; Dunn RM; Gratz S; Rave-Fränk M; Schmidberger H; Raue F; Becker W
    Cancer Res; 1997 Dec; 57(23):5309-19. PubMed ID: 9393755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments.
    Casey JL; Pedley RB; King DJ; Green AJ; Yarranton GT; Begent RH
    Br J Cancer; 1999 Nov; 81(6):972-80. PubMed ID: 10576653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Yttrium-90 chimeric L6 therapy of human breast cancer in nude mice and apoptosis-related messenger RNA expression.
    DeNardo SJ; Gumerlock PH; Winthrop MD; Mack PC; Chi SG; Lamborn KR; Shen S; Miers LA; deVere White RW; DeNardo GL
    Cancer Res; 1995 Dec; 55(23 Suppl):5837s-5841s. PubMed ID: 7493356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined radioimmunotherapy and radiotherapy of human colon carcinoma grafted in nude mice.
    Buchegger F; Rojas A; Delaloye AB; Vogel CA; Mirimanoff RO; Coucke P; Sun LQ; Raimondi S; Denekamp J; Pèlgrin A
    Cancer Res; 1995 Jan; 55(1):83-9. PubMed ID: 7805046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carcinoembryonic antigen expression of resurgent human colon carcinoma after treatment with therapeutic doses of 90Y-alpha-carcinoembryonic antigen monoclonal antibody.
    Esteban JM; Kuhn JA; Felder B; Wong JY; Battifora H; Beatty JD; Wanek PM; Shively JE
    Cancer Res; 1991 Jul; 51(14):3802-6. PubMed ID: 2065334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy with unlabeled and 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts.
    Buchsbaum DJ; Wahl RL; Normolle DP; Kaminski MS
    Cancer Res; 1992 Dec; 52(23):6476-81. PubMed ID: 1423295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
    Pegram M; Hsu S; Lewis G; Pietras R; Beryt M; Sliwkowski M; Coombs D; Baly D; Kabbinavar F; Slamon D
    Oncogene; 1999 Apr; 18(13):2241-51. PubMed ID: 10327070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined modality radioimmunotherapy with Taxol and 90Y-Lym-1 for Raji lymphoma xenografts.
    O'Donnell RT; DeNardo SJ; Miers LA; Kukis DL; Mirick GR; Kroger LA; DeNardo GL
    Cancer Biother Radiopharm; 1998 Oct; 13(5):351-61. PubMed ID: 10851425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin monoclonal antibodies.
    Behr TM; Sharkey RM; Juweid ME; Dunn RM; Ying Z; Zhang CH; Siegel JA; Goldenberg DM
    J Nucl Med; 1997 Mar; 38(3):409-18. PubMed ID: 9074529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapy of athymic mice bearing GW-39 human colonic cancer micrometastases with 131I-labeled monoclonal antibodies.
    Blumenthal RD; Sharkey RM; Haywood L; Natale AM; Wong GY; Siegel JA; Kennel SJ; Goldenberg DM
    Cancer Res; 1992 Nov; 52(21):6036-44. PubMed ID: 1394228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistology of carcinoembryonic antigen (CEA)-expressing tumors grafted in nude mice after radioimmunotherapy with 131I-labeled bivalent hapten and anti-CEA x antihapten bispecific antibody.
    Gautherot E; Kraeber-Bodéré F; Daniel L; Fiche M; Rouvier E; Saï-Maurel C; Thedrez P; Chatal JF; Barbet J
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3177s-3182s. PubMed ID: 10541361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody.
    Wong JY; Thomas GE; Yamauchi D; Williams LE; Odom-Maryon TL; Liu A; Esteban JM; Neumaier M; Dresse S; Wu AM; Primus FJ; Shively JE; Raubitschek AA
    J Nucl Med; 1997 Dec; 38(12):1951-9. PubMed ID: 9430476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.
    Baselga J; Norton L; Albanell J; Kim YM; Mendelsohn J
    Cancer Res; 1998 Jul; 58(13):2825-31. PubMed ID: 9661897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioimmunotherapy of human colonic cancer xenografts with 90Y labeled monoclonal antibodies to carcinoembryonic antigen.
    Sharkey RM; Kaltovich FA; Shih LB; Fand I; Govelitz G; Goldenberg DM
    Cancer Res; 1988 Jun; 48(11):3270-5. PubMed ID: 3365705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CaNa2EDTA for improvement of radioimmunodetection and radioimmunotherapy with 111In and 90Y-DTPA-anti-CEA MAbs in nude mice bearing human colorectal cancer.
    Watanabe N; Oriuchi N; Endo K; Inoue T; Kuroki M; Matsuoka Y; Tanada S; Murata H; Kim EE; Sasaki Y
    J Nucl Med; 2000 Feb; 41(2):337-44. PubMed ID: 10688120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.